Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.06-25 23:28

Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646041688?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-25 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646041688","market":"hk","top_or_hot":-1,"title":"Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?","media":"Simply Wall St.","content":"<div>\n<p>Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-25 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls","article_id":"2646041688","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646041688","pubTimestamp":1782401297,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug ivonescimab.\nSee our latest analysis for Summit Therapeutics.\nAgainst this backdrop, Summit Therapeutics’ share price return has fallen 14.26% over the past 30 days and 17.44% over 90 days. Its 1 year total shareholder return is down 33%, while the 3 year total shareholder return remains very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SMMT":"Summit Therapeutics PLC"},"translate_title":"Summit Therapeutics(SMMT)撤回5亿美元的发行后是否被低估了？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1.5},"content_text":"Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug ivonescimab. See our latest analysis for Summit Therapeutics. Against this backdrop, Summit Therapeutics’ share price return has fallen 14.26% over the past 30 days and 17.44% over 90 days. Its 1 year total shareholder return is down 33%, while the 3 year total shareholder return remains very large at over 4x. If this kind of event driven move has your attention, it may be a good moment to widen your watchlist and check out 38 healthcare AI stocks With Summit Therapeutics trading well below some valuation estimates but already reflecting big three year gains, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 51.2% Undervalued On the most followed narrative, Summit Therapeutics’ fair value of $29.18 sits well above the last close of $14.25. This puts the current share price against a much higher long term projection built on ivonescimab’s potential.  The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.  Read the complete narrative. Want to see what sits behind that valuation gap? The narrative leans heavily on aggressive revenue expansion, margin lift from today’s losses, and a much richer future earnings multiple. The real story is in how those moving parts stack together. Result: Fair Value of $29.18 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Summit Therapeutics’ single drug focus and heavy R&D spending, combined with unresolved FDA decisions on HARMONi, could quickly challenge this undervalued narrative. Find out about the key risks to this Summit Therapeutics narrative. Next Steps With sentiment on Summit Therapeutics clearly split between risks and rewards, it makes sense to move quickly and test the numbers yourself using 2 key rewards and 3 important warning signs Looking for more investment ideas beyond Summit Therapeutics? If Summit Therapeutics has sharpened your interest, do not stop there. Broaden your watchlist now with focused stock ideas that match different investing goals.  Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 44 high quality undervalued stocks. Prioritise resilience by reviewing stocks that appear on the 69 resilient stocks with low risk scores, where business strength and risk controls sit front and center. Hunt for lesser known opportunities by checking the screener containing 18 high quality undiscovered gems, which highlights companies with solid metrics that many investors may be overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646041688","isCrawlerRequest":true}